CA-HILLSTONE-NETWORKS
24.1.2023 08:01:36 CET | Business Wire | Press release
Hillstone Networks, a leading provider of innovative and accessible cybersecurity solutions, has announced a major upgrade to its operating system, Hillstone StoneOS 5.5R10. The latest upgrade delivers AI-based high performance threat protection, centralized Zero Trust control and management, and further simplification of security operations and system optimization, among over 300 new features. The new functionality enhances the security posture of customer environments and further streamlines security operations with an easy upgrade path.
Threat protection enhancements with AI technology
The new StoneOS leverages AI technology to provide ML-based threat detection for encrypted traffic without the need for decryption. It also features intelligent DDoS protection and DGA detection. In addition, included is a blacklist extension that empowers the Perimeter Traffic Filtering (PTF) function and delivers more protection against threats.
Centralized Zero Trust control and management
Advanced ZTNA implements centralized management for ZTNA policies through Hillstone Security Management (HSM), and supports intelligent connection to ZTNA gateways, single packet authentication (SPA), multiple vendor Operating System support for ZTNA clients, along with a ZTNA portal. The new features provide a better user experience with improved overall operations and management of the ZTNA solution.
Smarter interconnectivity with extended VPN capabilities
The extended VPN features support ECMP and failover for intelligent VPN routing and provide IPSec VPN tunnel establishment options by configuring custom ports and auto-negotiation. These features bring better bandwidth utilization and improve connectivity, ensuring the business remains undisrupted.
Streamlined system operations offload redundant workloads
The latest StoneOS introduces a simplified start-up wizard and automated NAT redundancy check to facilitate system operations, improving overall productivity for organizations by streamlining the workload of system administrators.
Robust system-wide enhancements further ensure business continuity
System availability is improved across the board in the latest release, with support for advanced High Availability (HA) and the graceful restart of Border Gateway Protocol (BGP), further ensuring that business services remain uninterrupted for organizations.
“The transition from the traditional, edge-based security model to the distributed workforce model is a seismic change, triggered primarily by the pandemic-induced work from home mandate, but the impact will evolve gradually, and therefore the solutions we deliver need to address the associated challenges,” states Tim Liu, CTO and co-founder, Hillstone Networks, “The latest iteration of StoneOS continues to address the challenges faced by SecOps teams, and the constant risks faced by enterprises globally. Enhanced AI-driven threat protection, better integration, centralized control and management, and streamlined operations are all critical in delivering a stable and strategic approach to cyber-resilient cybersecurity environments.”
StoneOS is the foundation for all Hillstone next-generation firewalls, which has been recognized in the 2022 Gartner® Magic Quadrant™ for Network Firewalls for the 9th consecutive year as a Visionary. StoneOS 5.5R10 is now generally available.
About Hillstone Networks
Hillstone Networks’ innovative and accessible cybersecurity solutions reshape enterprise security, enabling cyber resilience while lowering TCO. By providing comprehensive visibility, superior intelligence, and rapid protection to see, understand, and act against multilayer, multistage cyber threats, Hillstone is favorably rated by leading analysts and trusted by global companies. To learn more visit www.hillstonenet.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230123005067/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom